Unknown

Dataset Information

0

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.


ABSTRACT: The anti-HER2 antibody trastuzumab have shown clinical activity in combination with chemotherapy in different breast cancer settings. However, most of patients treated with this antibody progress after a period of treatment. Activation of the kinase SRC has been linked with resistance to trastuzumab in several preclinical studies. We designed a phase I clinical study to explore the activity of weekly trastuzumab (2 mg/kg) plus paclitaxel (80 mg/m2) in combination with the anti-SRC kinase inhibitor Dasatinib in the first line treatment of HER2 metastatic breast cancer. The primary objective was to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D); secondary objectives included efficacy, objective response rate (ORR), pharmacokinetics and pharmacodynamics. A "3+3" design guided dose escalation with two oral dose levels of dasatinib: 100mg (DL1) and 140 mg (DL2). 10 patients were included in the phase I part. Dasatinib 100 mg q.d. was established as the recommended RP2D. The median number of administered cycles was 12 (range, 1 to 18). Grade 3 treatment-related AEs at DL1 were diarrhea (n = 2), hyponatremia (n = 1), fatigue (n = 1), and AST/ALT elevation (n = 1). A significant reduction in p-SRC expression on epidermal keratinocytes on sequential skin biopsies was observed. In conclusion, we describe the feasibility of the combination of dasatinib, trastuzumab and paclitaxel, and its effect on proteins involved in trastuzumab resistance. The phase II part of this study is currently evaluating efficacy.

SUBMITTER: Ocana A 

PROVIDER: S-EPMC5641200 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.

Ocana Alberto A   Gil-Martin Marta M   Martín Miguel M   Rojo Federico F   Antolín Silvia S   Guerrero Ángel Á   Trigo José Manuel JM   Muñoz Montse M   Pandiella Atanasio A   Diego Núria Gonzalo NG   Bezares Susana S   Caballero Rosalía R   Carrasco Eva E   Urruticoechea Ander A  

Oncotarget 20170414 42


The anti-HER2 antibody trastuzumab have shown clinical activity in combination with chemotherapy in different breast cancer settings. However, most of patients treated with this antibody progress after a period of treatment. Activation of the kinase SRC has been linked with resistance to trastuzumab in several preclinical studies. We designed a phase I clinical study to explore the activity of weekly trastuzumab (2 mg/kg) plus paclitaxel (80 mg/m<sup>2</sup>) in combination with the anti-SRC kin  ...[more]

Similar Datasets

| S-EPMC6669497 | biostudies-literature
| S-EPMC6203283 | biostudies-literature
| S-EPMC9719636 | biostudies-literature
| S-EPMC4453846 | biostudies-other
| S-EPMC6342915 | biostudies-literature
| S-EPMC7409266 | biostudies-literature
| S-EPMC3950860 | biostudies-literature
| S-EPMC4313867 | biostudies-literature
| S-EPMC5017157 | biostudies-other
| S-EPMC6720931 | biostudies-literature